Beat AML Core Study

Completed

Conditions studied: Acute Myeloid Leukemia

In brief

In this study, DNA sequencing, computational biology modeling, and ex vivo drug sensitivity assays will be utilized to define clinically relevant gene mutations and identify potential therapeutics for patients with acute myeloid leukemia (AML).

Key facts

Study ID

NCT02927106

Run by

University of Florida

People needed

22

Starts

2017-02-15

Expected to finish

2020-07-29

Last updated by the study team

2020-08-05

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) as defined by World Health Organization 2016.
• ≥ 18 years of age
• Capable of providing informed consent

You may not qualify if…

• 17 years of age or less
• greater than 80 years of age

Where it is running

• UF Health Cancer Center — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.